Abstract

Background: Wide use of oxaliplatin as an antitumor drug is limited by severe neuropathy with pharmacoresistant cold hypersensitivity as the main symptom. Novel analgesics to attenuate cold hyperalgesia and new methods to detect drug candidates are needed. Methods: We developed a method to study thermal preference of oxaliplatin-treated mice and assessed analgesic activity of intraperitoneal duloxetine and pregabalin used at 30 mg/kg. A prototype analgesiameter and a broad range of temperatures (0–45 °C) were used. Advanced methods of image analysis (deep learning and machine learning) enabled us to determine the effectiveness of analgesics. The loss or reversal of thermal preference of oxaliplatin-treated mice was a measure of analgesia. Results: Duloxetine selectively attenuated cold-induced pain at temperatures between 0 and 10 °C. Pregabalin-treated mice showed preference towards a colder plate of the two used at temperatures between 0 and 45 °C. Conclusion: Unlike duloxetine, pregabalin was not selective for temperatures below thermal preferendum. It influenced pain sensation at a much wider range of temperatures applied. Therefore, for the attenuation of cold hypersensitivity duloxetine seems to be a better than pregabalin therapeutic option. We propose wide-range measurements of thermal preference as a novel method for the assessment of analgesic activity in mice.

Highlights

  • Oxaliplatin (trans-l-diaminocyclohexane oxalate platinum (II)) belongs to third-generation platinum-based chemotherapeutic agents

  • Chemotherapy-induced peripheral neuropathy (CIPN) comprises acute, transient neuropathy that is observed in almost 90% of patients within hours after oxaliplatin infusion, and a chronic form that occurs in 70% of oxaliplatin-treated patients

  • By studying thermal preference of neuropathic, oxaliplatin-treated mice exposed to pregabalin or duloxetine, we aimed to compare their effect on the thermal pain threshold at a wide range of temperatures applied

Read more

Summary

Introduction

Oxaliplatin (trans-l-diaminocyclohexane oxalate platinum (II)) belongs to third-generation platinum-based chemotherapeutic agents. Several potential mechanisms have been taken into consideration to establish phenomena underlying CIPN caused by oxaliplatin and currently it is thought that a rapid and non-enzymatic transformation of this drug to metabolites, such as oxalate, monochloro-, dichloro- and diaquodiaminocyclohexane platinum derivatives, is responsible for neurotoxicity of oxaliplatin. This metabolic pathway occurs in the blood plasma and it consists in the replacement of the oxalate moiety with chloride ions and water. We propose wide-range measurements of thermal preference as a novel method for the assessment of analgesic activity in mice

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call